increase or maintain our revenues from our Flexitouch System.•A recent change to the criteria for Medicare coverage for our products could have an adverse effect on our business and results of operations.•If we are unable to expand, manage and maintain our direct sales and marketing organizations, we may not be able to generate anticipated
The underwriters can exercise this option at any time within 30 days of this prospectus.Use of proceedsWe intend to use the net proceeds from this offering primarily to expand our sales, marketing, reimbursement, clinical, regulatory and product development activities, and the remainder
related notes included elsewhere in this prospectus.Year EndedDecember 31,Nine Months EndedSeptember 30,2014201520152016(In thousands, except share and per share data)Consolidated Statements of Operations Data:Revenues, net$47,736$62,872$41,712$56,064Cost of goods sold12,71516,90811,83915,417​​​​​​​​​​​​​​Gross profit35,02145,96429,87340,647​​​​​​​​​​​​​​Operating expenses:Sales and marketing18,15424,48517,29723,858Research and development2,8434,3122,9223,314Reimbursement, general and administrative10,22513,7169,44812,495​​​​​​​​​​​​​​Total operating expenses31,22242,51329,66739,667​​​​​​​​​​​​​​Income from operations3,7993,451206980Other income (expense)(4)(194)1820​​​​​​​​​​​​​​Income before income taxes3,7953,2572241,000Income tax expense1,7251,86490500​​​​​​​​​​​​​​Net income2,0701,393134500Convertible preferred stock dividends1,7611,8451,3961,247Allocation of undistributed earnings to preferred stockholders216———​​​​​​​​​​​​​​Net income (loss) attributable to common stockholders$93$(452)$(1,262)$(747)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Net income (loss) per common share attributable to common stockholders(1)Basic$0.04$(0.15)$(0.44)$(0.12)Diluted$0.02$(0.15)$(0.44)$(0.12)Weighted-average common shares outstanding used to compute net income (loss) per common share attributable
fails to achieve wide market acceptance for any reason, our business, financial condition and results of operations could be adversely affected.Our long-term growth depends on awareness and adoption of our products.A primary growth strategy is to establish our products as the standard of care for the treatment of lymphedema and chronic venous insufficiency.
include:•increased sales and marketing costs to increase awareness of our products;•costs to develop new and enhanced features for current products and research and development costs for new products;15Table of Contents•the time, resources, and expense required to develop and conduct clinical trials and seek additional regulatory clearances and approvals for
be adversely impacted.Our long-term growth depends on our ability to develop and commercialize additional products.The medical device industry is highly competitive and subject to rapid change and technological advancements.
factors, including our ability to:•properly identify and anticipate physician and patient needs;•develop and introduce new products or product enhancements in a timely manner;•avoid infringing upon the intellectual property rights of third-parties;•demonstrate the safety and efficacy of new products with data from clinical studies;•obtain the necessary regulatory clearances or approvals for new products or product enhancements;•be fully FDA-compliant with the development, manufacturing and marketing of new devices or modified products;17Table of Contents•provide adequate training to potential users of our products;•secure adequate coverage and reimbursement for our products; and•develop an effective and dedicated sales and marketing team.If
factors that may cause fluctuation in our quarterly results or variations from our forecasts include:•physician adoption of our products;•timing of new product offerings, acquisitions, licenses or other significant events by us or our competitors;•unanticipated pricing pressure;•the hiring, retention and continued productivity of our sales representatives;•our ability to expand the geographic reach of our sales and marketing efforts;•our ability to obtain regulatory clearance or approval for our products in development or for our current products outside the United States;•the impact of results from clinical research and trials on our existing products and products in development;•delays in receipt of anticipated purchase orders;•delays in, or failure of, component deliveries from our suppliers; and•positive or negative coverage in the media or clinical publications of our products or products of our competitors or our industry.18Table of ContentsIn the event our actual revenues and operating results do not meet our forecasts or the forecasts or estimates of the research analysts that cover us for a particular period,
of risks associated with international operations could impact our strategy and adversely affect our future growth.We expect that we would be subject to additional risks related to entering into international markets, including:•difficulty successfully training patients and physicians on using our products;•difficulty hiring a qualified direct-sales force or finding and entering into commercially-acceptable agreements with suitable third-parties to
market our products;•reduced protection for intellectual property rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation, or political instability in particular foreign economies and markets;•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;•foreign taxes, including withholding of payroll taxes;•foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing
business in another country;25Table of Contents•workforce uncertainty in countries where labor unrest is more common than in the United States;•international regulators and third-party payers may require additional clinical studies prior to approving or allowing reimbursement for our
retroactive taxes and penalties, which could have a material adverse effect on our business, financial condition and operating results.We contract with over 300 licensed healthcare practitioners as home trainers, who educate our patients on the proper use of our solutions.
contractors, which could have a material adverse effect on our business, financial condition and results of operations.Risks Relating to Government RegulationWe are subject to extensive federal and state regulation, and if we fail to comply with applicable
which future legislation and regulatory changes could have a material adverse effect on our business, financial condition and results of operations.We are subject to significant regulation by numerous government agencies, including the FDA.
marketing a modified device until we obtain a new 510(k) clearance or premarket approval, our business, financial condition, operating results and future growth prospects could be materially adversely
liability claims could divert management's attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance.Our products may cause or contribute to adverse medical events that we are required to report to the FDA, and
continue to fluctuate, and a large negative payment adjustment could adversely affect our business, financial conditions and results of operations.We are subject to additional federal, state and foreign laws and regulations relating to our healthcare
Any future funding requirements will depend on many factors, including:•market acceptance of our products;•the scope, rate of progress and cost of our clinical studies;•the cost of our research and development activities;•the cost of filing and prosecuting patent applications and defending and enforcing our patent or other intellectual property rights;•the cost of defending, in litigation or otherwise, any claims that we infringe third-party patents or other intellectual property rights;•the cost and timing of additional regulatory clearances or approvals;•the cost and timing of establishing additional sales, marketing and distribution capabilities;•costs associated with any product recall that may occur;•the effect of competing technological and market developments;42Table of Contents•the extent to which we acquire or invest in products, technologies and businesses, although we currently have no commitments or agreements
research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.•Ownership of our patents or patent applications may be challenged by third parties.•The patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.48Table of ContentsConfidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets